File Download
There are no files associated with this item.
Supplementary
-
Citations:
- Appears in Collections:
Book Chapter: Management of Relapsed or Refractory AML
| Title | Management of Relapsed or Refractory AML |
|---|---|
| Authors | |
| Issue Date | 28-Sep-2023 |
| Publisher | Springer Nature Singapore |
| Abstract | Standard induction chemotherapy for acute myeloid leukemia (AML) results in a remission rate of around 70%. Up to 30% of patients do not achieve a remission and approximately 50% of patients who achieve complete remission after standard frontline induction chemotherapy relapse. Outcome with conventional approaches in relapsed or refractory AML is poor and only a minority of patients achieve long-term cure. Results from various novel agents and combinations in relapsed or refractory AML have only shown response rates between 30% and 55%. In patients achieving remission after re-induction and undergoing allogeneic hematopoietic stem cell transplantation (HSCT), overall survival rates range between 20% and 55% at 2 years. In this chapter, we outline the current and upcoming approaches in optimizing the management of patient with relapsed or refractory acute myeloid leukemia. |
| Persistent Identifier | http://hdl.handle.net/10722/341833 |
| ISBN |
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Singh, Gill Harinder Harry | - |
| dc.date.accessioned | 2024-03-26T05:37:33Z | - |
| dc.date.available | 2024-03-26T05:37:33Z | - |
| dc.date.issued | 2023-09-28 | - |
| dc.identifier.isbn | 9789819938094 | - |
| dc.identifier.uri | http://hdl.handle.net/10722/341833 | - |
| dc.description.abstract | <p>Standard induction chemotherapy for acute myeloid leukemia (AML) results in a remission rate of around 70%. Up to 30% of patients do not achieve a remission and approximately 50% of patients who achieve complete remission after standard frontline induction chemotherapy relapse. Outcome with conventional approaches in relapsed or refractory AML is poor and only a minority of patients achieve long-term cure. Results from various novel agents and combinations in relapsed or refractory AML have only shown response rates between 30% and 55%. In patients achieving remission after re-induction and undergoing allogeneic hematopoietic stem cell transplantation (HSCT), overall survival rates range between 20% and 55% at 2 years. In this chapter, we outline the current and upcoming approaches in optimizing the management of patient with relapsed or refractory acute myeloid leukemia.<br></p> | - |
| dc.language | eng | - |
| dc.publisher | Springer Nature Singapore | - |
| dc.relation.ispartof | Pathogenesis and Treatment of Leukemia | - |
| dc.title | Management of Relapsed or Refractory AML | - |
| dc.type | Book_Chapter | - |
| dc.identifier.doi | 10.1007/978-981-99-3810-0_9 | - |
| dc.identifier.eisbn | 9789819938100 | - |